Viking Therapeutics Showcases VK2735 Obesity Clinical Data at ObesityWeek 2025
Reuters
Oct 30
<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Showcases VK2735 Obesity Clinical Data at ObesityWeek 2025
Viking Therapeutics Inc. has announced upcoming presentations related to its VK2735 obesity program at major medical conferences in 2025. At ObesityWeek® 2025, being held from November 4-7 in Atlanta, the company will present results from an exploratory analysis of the Phase 2 VENTURE clinical trial, which evaluated 13 weeks of weekly subcutaneous VK2735 treatment in obese subjects, focusing on its impact on prediabetes and metabolic syndrome. Additionally, Viking will present the design of its ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in adults with overweight or obesity and at least one weight-related co-morbid condition. The company will also make two presentations at the American Heart Association Scientific Sessions 2025 in New Orleans from November 7-10. These will include the design of the ongoing Phase 3 VANQUISH-2 study of subcutaneous VK2735 in Type 2 diabetes patients with obesity or overweight, and results of an analysis on the prevalence of cardiometabolic conditions across different body mass index categories. All presentations are scheduled for future dates.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA09461) on October 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.